Healthcare provider profile · identity verified

Chinta Tony Chiu, MD

Internal Medicine · FLUSHING, NY · NPI 1710991245

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	211	53
Amlodipine Besylate	Amlodipine Besylate	201	52
Losartan Potassium	Losartan Potassium	156	41
Rosuvastatin Calcium	Rosuvastatin Calcium	154	45
Famotidine	Famotidine	152	57
Metformin Hcl Er	Metformin Hcl	120	35
Omeprazole	Omeprazole	106	32
Metoprolol Succinate	Metoprolol Succinate	98	31
Tamsulosin Hcl	Tamsulosin Hcl	86	30
Levothyroxine Sodium	Levothyroxine Sodium	85	22
Finasteride	Finasteride	84	22
Fluticasone Propionate	Fluticasone Propionate	84	29
Lisinopril	Lisinopril	84	19
Telmisartan	Telmisartan	82	21
Vascepa	Icosapent Ethyl	77	16
Promethazine Hcl	Promethazine Hcl	72	48
Lovastatin	Lovastatin	70	22
Ammonium Lactate	Ammonium Lactate	65	25
Cefuroxime	Cefuroxime Axetil	63	52
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	61	30
Zolpidem Tartrate	Zolpidem Tartrate	60	16
Ezetimibe	Ezetimibe	53	13
Jardiance	Empagliflozin	52	14
Simvastatin	Simvastatin	50	11
Raloxifene Hcl	Raloxifene Hcl	49	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	48	17
Pioglitazone Hcl	Pioglitazone Hcl	46	19
Trazodone Hcl	Trazodone Hcl	45	17
Metformin Hcl	Metformin Hcl	42	suppressed
Tradjenta	Linagliptin	37	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	36	32
Triamcinolone Acetonide	Triamcinolone Acetonide	36	22
Xarelto	Rivaroxaban	35	suppressed
Allopurinol	Allopurinol	33	suppressed
Farxiga	Dapagliflozin Propanediol	32	suppressed
Glipizide Er	Glipizide	31	suppressed
Linzess	Linaclotide	31	suppressed
Naproxen	Naproxen	31	23
Diclofenac Epolamine	Diclofenac Epolamine	29	suppressed
Atenolol	Atenolol	28	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	28	suppressed
Montelukast Sodium	Montelukast Sodium	28	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	28	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	26	suppressed
Donepezil Hcl	Donepezil Hcl	26	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	26	suppressed
Januvia	Sitagliptin Phosphate	24	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	23	suppressed
Vemlidy	Tenofovir Alafenamide	23	suppressed
Clopidogrel	Clopidogrel Bisulfate	22	suppressed
Irbesartan	Irbesartan	22	suppressed
Tramadol Hcl	Tramadol Hcl	22	suppressed
Meclizine Hcl	Meclizine Hcl	21	15
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	21	15
Ketoconazole	Ketoconazole	20	suppressed
Nifedipine Er	Nifedipine	20	suppressed
Celecoxib	Celecoxib	19	14
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	19	12
Metoprolol Tartrate	Metoprolol Tartrate	19	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	17	suppressed
Easy Touch Alcohol Prep Pads	Alcohol Antiseptic Pads	17	suppressed
Gabapentin	Gabapentin	17	suppressed
Myrbetriq	Mirabegron	16	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	15	suppressed
Diclofenac Sodium	Diclofenac Sodium	14	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	14	suppressed
Fenofibrate	Fenofibrate,micronized	14	suppressed
Gemfibrozil	Gemfibrozil	14	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Mupirocin	Mupirocin	14	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	13	suppressed
Furosemide	Furosemide	13	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	13	suppressed
Valsartan	Valsartan	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	11
Colchicine	Colchicine	12	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	12	suppressed
Procto-Med Hc	Hydrocortisone	12	suppressed
Carvedilol	Carvedilol	11	suppressed
Folic Acid	Folic Acid	11	suppressed
Glimepiride	Glimepiride	11	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error